NEW REALITIES IN THE TREATMENT OF DISSEMINATED SKIN MELANOMA WITH BRAF MUTATION


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Disseminated skin melanoma (DSM) is a malignant neoplasm with one of the highest mortality rates in the world. Low effectiveness of chemotherapy necessitates exploration of new groups of drugs for the treatment of DSM. The discovery of BRAF-mutation and the development of BRAF-inhibitors have significantly improved the results of treatment of the DSM, and changed the quality of life of patients. According to recent studies, the combination of targeted drugs is more effective than monotherapy. Now, combination of BRAF- and MEK-inhibitors (vemurafenib+cobimetinib) can be considered as a new standard for high effective treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation.

Texto integral

Acesso é fechado

Sobre autores

M. Abramov

FSBI "RORC n.a. N.N. Blokhin" of RMH PhD, Senior Researcher at the Department of Chemotherapy and Combined Therapy of Malignant Tumors Moscow

O. Gordeeva

FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow

E. Borisova

FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow

S. Gutorov

FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow

G. Vyshinskaya

FSBI "RORC n.a. N.N. Blokhin" of RMH Moscow

Bibliografia

  1. Luke J.J., Schwartz G.K. Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma. Clin. Dermatol. 2013;31(3): 290-97.
  2. Lves N.J., Stowe R.L., Lorigan P., Wheatley K. Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients. J. Clin. Oncol. 2007;25:5426-34.
  3. Alexandrov L.B. Nik-Zainal S., Wedge D.C., et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
  4. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P, Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A.; BRIM-3 Study Group. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N. Engl. J. Med. 2011;364(26):2507-16.
  5. Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., Kefford R.F., Scolyer R.A., Long G.V. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2012;18:3242-49.
  6. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010;363:809-19.
  7. Ribas A., Kim K.B., Schuchter L.M., et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutationpositive melanoma. J. Clin. Oncol. 2011;29(Suppl):8509. abstr.
  8. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A., Garbe C., Testori A., Maio M., Lorigan P., Lebbé C., Jouary T., Schadendorf D., O'Day S.J., Kirkwood J.M., Eggermont A.M., Dréno B., Sosman J.A., Flaherty K.T., Yin M., Caro I., Cheng S., Trunzer K., Hauschild A. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-32.
  9. Ribas A., Gonzalez R., Pavlick A., Hamid O., Gajewski T.F., Daud A., Flaherty L., Logan T., Chmielowski B., Lewis K., Kee D., Boasberg P., Yin M., Chan I., Musib L., Choong N., Puzanov I., McArthur G.A. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954-65.
  10. Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N. Engl. J. Med. 2014;371:1867-76.
  11. de la Cruz-Merino L., et al. Clinical features of cobimetinib (COBI) - associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study. J. Clin. Oncol. 2015;33(suppl):abstr. 9033.
  12. Ascierto P.A., McArthur G.A,, Dréno B., Atkinson V., Liszkay G., Di Giacomo A.M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Yan Y., Wongchenko M., Chang I., Hsu J.J., Koralek D.O., Rooney I., Ribas A., Larkin J. Cobimetinib combined with vemurafenib in advanced BRAFV600 - mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-60.
  13. Harding J.J., Catalanotti F., Munhoz R.R., Cheng D.T., Yaqubie A., Kelly N., McDermott G.C., Kersellius R., Merghoub T., Lacouture M.E., Carvajal R.D., Panageas K.S., Berger M.F., Rosen N., Solit D.B., Chapman P.B. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist. 2015;20(7):789-97.
  14. Ugurel S., Loquai C., Kähler K., Hasse lJ., Berking C., Zimmer L., Haubitz I., Satzger I., Müller-Brenne T., Mikhaimer N.C., Becker J.C., Kilian K.J., Schadendorf D., Heinzerling L., Kaatz M., Utikal J., Göppner D., Pföhler C., Pflugfelder A., Mössner R., Gutzmer R.; Dermatologic Cooperative Oncology Group (DeCOG). A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol. 2015;26(3):573-82.
  15. Massi D., Brusa D., Merelli B., Falcone C., Xue G., Carobbio A., Nassini R., Baroni G., Tamborini E., Cattaneo L., Audrito V., Deaglio S., Mandalà M. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann. Oncol. 2015;26:1980-87.
  16. Flaherty K.T., et al. ASCO Meeting, 2016.
  17. TCGA, Cell, 2015.
  18. Shi H., Hong A., Kong X., Koya R.C., Song C., Moriceau G., Hugo W., Yu C.C., Ng C., Chodon T., Scolyer R.A., Kefford R.F., Ribas A., Long G.V., Lo R.S. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4:69-79.
  19. Trunzer K., Pavlick A.C., Schuchter L., Gonzalez R., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Kim K.B., Weber J.S., Hersey P., Long G.V., Lawrence D., Ott P.A., Amaravadi R.K., Lewis K.D., PuzanovI., Lo R.S., Koehler A., Kockx M., Spleiss O., Schell-Steven A., Gilbert H.N., Cockey L., Bollag G., Lee R.J., Joe A.K., Sosman J.A., Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 2013;31:1767-74.
  20. Paraiso K., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., Messina J.L., Flaherty K.T., Smalley K.S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer. 2010;102: 1724-30.
  21. Long G.V., et al. J. Clin.Oncol.2014;32(5S):9011.
  22. Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014;371:1867-76.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies